Angiopoietin-2: A Potential Mediator of the Glycocalyx Injury in Adult Nephrotic Patients

Introduction: Glomerulopathy is a group of diseases that affect mainly young adults between the ages of 20 and 40 years. Recently, it has been demonstrated that syndecan-1, a biomarker of endothelial glycocalyx damage, is increased in nephrotic patients with near-normal renal function and it is important to endothelial dysfunction in these patients. Angiopoietin-2 (AGPT2) is an endothelial growth factor that promotes cell derangement. Here we evaluated AGPT2 levels in patients with nephrotic syndrome, near-normal renal function and the possible interaction of AGPT2 with endothelial glycocalyx derangement. Methods: This was a cross-sectional study performed from January through November 2017. Adult patients (age > 18 years) with nephrotic syndrome and without immunosuppression were included. Blood samples were drawn after a 12 h fast for later measurement of syndecan-1 and AGPT2. Mediation analyses were performed to assess the hypothesized associations of nephrotic syndrome features and AGPT2 with syndecan-1. Results: We included 65 patients, 37 (56.9%) of them female, with primary glomerular disease. Syndecan-1 in nephrotic patients was higher than in control individuals (102.8 ± 36.2 vs. 28.2 ± 9.8 ng/mL, p < 0.001). Correlation of syndecan-1 with the main features of nephrotic syndrome after adjustment for age and estmmated glomerular filtration rate (eGFR) demonstrated that syndecan-1 was significantly associated with 24-h urinary protein excretion, total cholesterol, LDL (low density lipoprotein)-cholesterol, HDL (high-density lipoprotein)-cholesterol, and triglycerides. Angiopoietin-2 was independently associated with serum albumin, 24 h urinary protein excretion, total cholesterol, and LDL-cholesterol, in addition to being strongly associated with syndecan-1 (0.461, p < 0.001). The results of the mediation analyses showed that the direct association between LDL-cholesterol and syndecan-1 was no longer significant after AGPT-2 was included in the mediation analysis. AGPT2 explained 56% of the total observed association between LDL-cholesterol and syndecan-1. Conclusion: The association between LDL-cholesterol and glycocalyx derangement in nephrotic patients is possibly mediated by AGPT2.

[1]  R. Boon,et al.  Endothelial Cell Metabolism in Atherosclerosis , 2018, Front. Cell Dev. Biol..

[2]  Theis Lange,et al.  Applied mediation analyses: a review and tutorial , 2017, Epidemiology and health.

[3]  M. Lanaspa,et al.  Angiopoietin-like-4 and minimal change disease , 2017, PloS one.

[4]  D. Min,et al.  Association of genetic polymorphisms of angiopoietin-like 4 with severity of posttransplant proteinuria in kidney allograft recipients. , 2017, Transplant immunology.

[5]  S. Ishibe,et al.  Targeting the podocyte cytoskeleton: from pathogenesis to therapy in proteinuric kidney disease. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  N. Vaziri.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. , 2016, Kidney international.

[7]  Y. Oike,et al.  Angiopoietin-like protein 2 increases renal fibrosis by accelerating transforming growth factor-β signaling in chronic kidney disease. , 2016, Kidney international.

[8]  G. Meneses,et al.  Glycocalyx injury in adults with nephrotic syndrome: Association with endothelial function. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[9]  V. Gudnason,et al.  Mediation analysis of aortic stiffness and renal microvascular function. , 2015, Journal of the American Society of Nephrology : JASN.

[10]  H. Pavenstädt,et al.  Damage of the endothelial glycocalyx in chronic kidney disease. , 2014, Atherosclerosis.

[11]  S. Kersten,et al.  Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome , 2013, Nature Medicine.

[12]  A. Hayes.  Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach , 2013 .

[13]  K. Wu,et al.  Angiopoietin-2 Is Associated with Albuminuria and Microinflammation in Chronic Kidney Disease , 2013, PloS one.

[14]  K. Matrawy,et al.  Angiopoietin-2, endothelial dysfunction and renal involvement in patients with systemic lupus erythematosus. , 2012, Journal of nephrology.

[15]  J. Krischer,et al.  Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis , 2012, PloS one.

[16]  D. Fliser,et al.  Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  Markus Thomas,et al.  The role of the Angiopoietins in vascular morphogenesis , 2009, Angiogenesis.

[18]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[19]  A. Woolf,et al.  Roles of angiopoietins in kidney development and disease. , 2009, Journal of the American Society of Nephrology : JASN.

[20]  R. Bilous,et al.  Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. , 2007, Journal of the American Society of Nephrology : JASN.

[21]  R. Hiatt,et al.  The increased risk of coronary heart disease associated with nephrotic syndrome. , 1993, Kidney international.

[22]  S. Agrawal,et al.  Dyslipidaemia in nephrotic syndrome: mechanisms and treatment , 2018, Nature Reviews Nephrology.

[23]  H. Pavenstädt,et al.  Endothelial glycocalyx breakdown is mediated by angiopoietin-2. , 2017, Cardiovascular research.

[24]  B. Kasiske,et al.  KDIGO Clinical Practice Guideline for Glomerulonephritis , 2012 .

[25]  A. Kautzky-Willer,et al.  CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study , 2022 .